Login to Your Account

Up to $145M in Milestones Per Program

Evotec, J&J Dig Deeper into AD: Deal Seeking Molecular Triggers

By Randy Osborne
Staff Writer

Thursday, November 7, 2013
The Johnson & Johnson (J&J) Innovation Center, through J&J unit Janssen Pharmaceuticals Inc., is pledging up to $10 million up front per program, followed by as much as $145 million more for each, in a deal with Evotec AG that aims to find and target the true originators of Alzheimer’s disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription